Roche Holding AG’s experimental breast-cancer pill failed to meet the main goal of a study, a blow to the drugmaker’s efforts to develop a next-generation hormone therapy that caused the shares to plunge.
Patients treated with Roche’s giredestrant and an older drug developed by Pfizer Inc. were no more likely to live without their cancer worsening than those given standard therapy, the Swiss drugmaker said Monday.
The pill is Roche’s most advanced next-generation hormone therapy, part of a new class known as selective estrogen receptor degraders — the first major innovation in this type of breast cancer treatment ...
